학술논문

Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Document Type
Article
Source
Expert Opinion on Pharmacotherapy; Mar2024, Vol. 25 Issue 4, p477-484, 8p
Subject
IMMUNOLOGICAL adjuvants
TRIPLE-negative breast cancer
CANCER chemotherapy
PROGRESSION-free survival
TOXICITY testing
Language
ISSN
14656566
Abstract
Copyright of Expert Opinion on Pharmacotherapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)